Mirum Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $5.21B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $176.20M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $159.90M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | $149.00M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $133.00M | $0.05 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $127.80M | $-0.12 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $111.60M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | $99.41M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | $77.88M | $-0.52 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | $69.20M | $-0.54 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | After market close | $69.55M | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| net product sales guidance | 2026 | $680.00M to $700.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Mirum Pharmaceuticals filed with the SEC
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare
Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
J a n u a r y 2 0 2 6 Mirum Pharmaceuticals: Delivering High Impact Medicines for Rare Disease Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Mirum Pharmaceuticals Announces Additional Private Placement Financing with TCGx
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iru m t o Ac q u ir e B lu e ja y T h e r ap e u t ic s D e c e m b e r 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
J a n u a r y 2 0 2 5 Mirum Pharmaceuticals: Transforming Lives in Rare Disease Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Transforming Lives in Rare Disease Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Unless the content otherwise requires, the terms Mirum, company, our, us, and we in this
Other events · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Transforming Lives in Rare Disease Exhibit 99.2
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
LIVMARLI in the United States and rest of world; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; estimates of the number of patients impacted by ALGS,
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MARCH-PFIC Phase 3 Topline Results
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K